International Assets Investment Management LLC Buys 8,600 Shares of ChromaDex Co. (NASDAQ:CDXC)

International Assets Investment Management LLC boosted its holdings in shares of ChromaDex Co. (NASDAQ:CDXC) by 43.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 28,600 shares of the company’s stock after purchasing an additional 8,600 shares during the quarter. International Assets Investment Management LLC’s holdings in ChromaDex were worth $410,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of the business. Silverberg Bernstein Capital Management LLC purchased a new stake in ChromaDex during the fourth quarter valued at $118,000. Connor Clark & Lunn Investment Management Ltd. raised its stake in ChromaDex by 121.9% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 83,031 shares of the company’s stock valued at $121,000 after purchasing an additional 45,618 shares in the last quarter. Gabelli Funds LLC raised its stake in ChromaDex by 9.1% during the third quarter. Gabelli Funds LLC now owns 180,000 shares of the company’s stock valued at $263,000 after purchasing an additional 15,000 shares in the last quarter. Finally, Gamco Investors INC. ET AL raised its stake in ChromaDex by 26.5% during the third quarter. Gamco Investors INC. ET AL now owns 259,850 shares of the company’s stock valued at $379,000 after purchasing an additional 54,500 shares in the last quarter. Hedge funds and other institutional investors own 15.41% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on CDXC. Roth Mkm increased their target price on shares of ChromaDex from $4.25 to $6.00 and gave the company a “buy” rating in a research note on Tuesday, April 9th. StockNews.com began coverage on shares of ChromaDex in a research note on Sunday, March 3rd. They issued a “strong-buy” rating on the stock.

ChromaDex Trading Down 0.3 %

Shares of CDXC opened at $3.39 on Friday. The company has a market cap of $255.30 million, a P/E ratio of -48.42 and a beta of 1.99. ChromaDex Co. has a twelve month low of $1.25 and a twelve month high of $4.65. The company’s fifty day simple moving average is $2.85 and its 200-day simple moving average is $1.92.

ChromaDex Company Profile

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.